Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Up 106.8% in August

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 242,001 shares, an increase of 106.8% from the August 15th total of 117,037 shares. Based on an average daily volume of 151,797 shares, the short-interest ratio is currently 1.6 days. Currently, 4.7% of the shares of the stock are sold short.

Jaguar Animal Health Trading Up 1.5%

JAGX stock traded up $0.00 during mid-day trading on Wednesday, reaching $0.23. 70,564 shares of the stock traded hands, compared to its average volume of 149,706. Jaguar Animal Health has a 52-week low of $0.20 and a 52-week high of $85.40. The stock’s fifty day moving average is $1.02 and its 200-day moving average is $6.42. The company has a market cap of $1.18 million, a P/E ratio of -0.00 and a beta of -0.07. The company has a current ratio of 0.69, a quick ratio of 0.40 and a debt-to-equity ratio of 0.35.

Shares of Jaguar Animal Health are set to reverse split before the market opens on Thursday, September 17th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, September 16th.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($52.15) by $36.45. The firm had revenue of $1.23 million for the quarter, compared to analyst estimates of $4.24 million.

Analyst Ratings Changes

Several analysts recently commented on JAGX shares. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.